Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Mounjaro (tirzepatide) hasnt been tested in a published osteoarthritis trial yet
.webp)
What we'd expect long-term based on available data: Weight loss continues through at least 104 weeks in most patients Estimated peak loss: 3032% in patients reaching maximum dose and maintaining treatment Maintenance phase: stable weight if treatment continues without dose reduction Weight regain after stopping is near-universal with all GLP-1 medications
Final Thoughts Semaglutide represents a major advancement in both diabetes management and the medical treatment of obesity
Read our July 2025 to January 2026 update about pill press seizures, policy developments, and legislation
For microdosing protocols, the microdosing tirzepatide chart provides specific syringe readings at fractional doses
![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)
